These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 25623277

  • 21. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
    Hudson M, Richard H, Pilote L.
    BMJ; 2005 Jun 11; 330(7504):1370. PubMed ID: 15947399
    [Abstract] [Full Text] [Related]

  • 22. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
    Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A.
    Ann Allergy Asthma Immunol; 2005 Aug 11; 95(2):154-8. PubMed ID: 16136765
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.
    Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235
    [Abstract] [Full Text] [Related]

  • 25. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ, Bolognese JA, Yu C, Krupa D, Curtis S.
    Curr Med Res Opin; 2004 Dec 09; 20(12):1899-908. PubMed ID: 15701208
    [Abstract] [Full Text] [Related]

  • 26. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.
    Am J Cardiol; 2007 Jan 01; 99(1):91-8. PubMed ID: 17196469
    [Abstract] [Full Text] [Related]

  • 27. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Jan 01; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 28. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN.
    Rheumatology (Oxford); 2007 Feb 01; 46(2):265-72. PubMed ID: 16844699
    [Abstract] [Full Text] [Related]

  • 29. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan.
    Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS.
    Pharmacoepidemiol Drug Saf; 2011 Jul 01; 20(7):763-71. PubMed ID: 21618340
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Jul 01; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.
    Croom KF, Siddiqui MA.
    Drugs; 2009 Jul 30; 69(11):1513-32. PubMed ID: 19634927
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May 30; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 38. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK, Castellsague J, Walker AM.
    Pharmacoepidemiol Drug Saf; 2008 Oct 30; 17(10):982-8. PubMed ID: 18711705
    [Abstract] [Full Text] [Related]

  • 39. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans.
    Roughead EE, Ramsay E, Pratt N, Gilbert AL.
    Drug Saf; 2008 Oct 30; 31(11):997-1003. PubMed ID: 18840019
    [Abstract] [Full Text] [Related]

  • 40. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 30; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.